Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will have its Chief Financial Officer, Eli Kalif, present at the Barclays Global Healthcare Conference on March 14, 2023, at 10:15 A.M. Eastern Time. Investors can access a live webcast of the presentation via Teva's Investor Relations website. A recorded version will be available within 24 hours and can be accessed for up to 90 days. Teva is recognized for its extensive portfolio of over 3,500 products and plays a crucial role in global healthcare, serving approximately 200 million patients daily.
Summary not available.
Summary not available.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has initiated tender offers with a maximum purchase price of
Teva Pharmaceuticals has announced the presentation of new data on its Digihaler System at the AAAAI 2023 Annual Meeting from February 24-27 in San Antonio, Texas. The data focuses on the smart inhaler’s benefits in asthma management, showcasing findings from the CONNECT2 clinical trial. Highlights include real-world usage patterns, adherence relationships, and barriers to implementing digital inhaler technology. The Digihaler System is touted as the first to provide objective data for personalized asthma treatment. Senior Medical Director Tanisha Hill underscores the importance of this data in enhancing patient care and treatment personalization.
Teva Pharmaceuticals announced the launch of the IMPACT-TD Scale, a standardized assessment for measuring the burden of tardive dyskinesia (TD) beyond just movement severity. Developed in collaboration with the TD community, the scale incorporates insights from patients, caregivers, and healthcare providers. It categorizes TD's impact into various areas such as social, psychological, and vocational aspects, aiming to enhance patient dialogue and comprehensive understanding. With 780,000 affected individuals in the U.S., this tool is expected to improve monitoring and overall management of TD, following a consensus published in the Journal of Clinical Psychiatry in November 2022.
Teva Pharmaceuticals has received FDA approval for AUSTEDO XR (deutetrabenazine) extended-release tablets, a once-daily treatment for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). This new formulation is available in 6 mg, 12 mg, and 24 mg strengths, providing a convenient option that may reduce pill burden for patients. AUSTEDO XR is the only VMAT2 inhibitor with long-term efficacy data for these conditions, offering sustained treatment options. Teva aims to facilitate patient adherence with this innovation, expected to be available in the U.S. later this year.
Teva Pharmaceuticals has settled Florida's price-fixing claims, agreeing to pay $6.73 million. The settlement resolves the state's claims, allowing Teva to focus on compliance and business operations. This marks Teva's fifth settlement regarding price-fixing allegations, with payments reflecting the state's population share. The amount falls within estimated provisions made in Q3 2022. Teva maintains its commitment to quality and antitrust compliance while continuing discussions with other states to settle similar claims.
Teva Pharmaceutical Industries Ltd. reported a net loss of $2.35 billion for 2022, with a diluted loss per share of $2.12. Total revenues for the year were $14.9 billion, a 6% decrease from 2021, attributed to lower sales of COPAXONE and respiratory products. For Q4 2022, revenues were $3.9 billion, while GAAP diluted EPS stood at $(1.10). The company anticipates revenues in 2023 to range between $14.8 - $15.4 billion, with adjusted EBITDA expected at $4.5 - $4.9 billion. Positive momentum was noted in innovative products like AUSTEDO and AJOVY, which drove significant growth.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that its greenhouse gas (GHG) emission reduction targets have been approved by the Science Based Targets initiative (SBTi). These targets aim for a 46% reduction in absolute scope 1 and 2 GHG emissions by 2030 and a 25% reduction in absolute scope 3 emissions. The initiative aligns with a 1.5°C climate pathway. Teva's sustainable financing strategy includes a $5 billion sustainability-linked bond, the largest in its sector. The company emphasizes the connection between health and environmental sustainability as part of its corporate social responsibility.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
